Diamyd Medical starts producing proprietary GABA drug and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Diamyd Medical starts producing proprietary GABA drug and expands its Scientific Advisory Board

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) today announced that production of a proprietary GABA drug has started. Concurrently, the Scientific and Medical Advisory Board is expanded with two leading experts in rheumatoid arthritis and type 2 diabetes, Professor Daniel Furst, University of California, Los Angeles (UCLA) and Associate Professor Michael Alvarsson, Clinic Director at the Karolinska University Hospital. Diamyd Medical has as previously reported broadened its operations to include type 2 diabetes and rheumatoid arthritis with its own GABA drug. Development of a GABA-drug product has now been launched in collaboration with a supplier of GMP production and preclinical studies to determine the dose and formulation start shortly. To further strengthen its expertise in type 2 diabetes and rheumatoid arthritis, Diamyd Medical has expanded its Scientific and Medical Advisory Board with two new members, Professor Daniel Furst and Associate Professor Michael Alvarsson. Daniel Furst, Professor at the University of California, Los Angeles (UCLA) and rheumatologist, has published over 800 articles and 15 books, including 430 scientific publications, in his field. Doctor Furst’s research include clinical pharmacology of anti-rheumatic drugs and the pathophysiology and treatment of systemic sclerosis. Michael Alvarsson is Senior Consultant Physician at the Department of Endocrinology, Metabolism and Diabetes at Karolinska University Hospital and Associate Professor at the Karolinska Institute, where he conducts clinical diabetes research at the Department of Molecular Medicine and Surgery. Doctor Alvarsson has long experience from clinical studies in type 2 diabetes as principal investigator for numerous multinational clinical trials. About Diamyd Medical Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Six clinical studies are ongoing with Diamyd®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB (former Cellaviva AB). Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser. För ytterligare information, kontakta: Ulf Hannelius, vd Tel: +46 736 35 42 41. E-post: ulf.hannelius@diamyd.com Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8 661 63 68 E-post: info@diamyd.com Org. nr: 556242-3797 Hemsida: www.diamyd.com Denna information är sådan information som Diamyd Medical är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 1 november 2016 kl 08.30 CET

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 5

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 5

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
Machine Grabs Prime Dallas Property Amid Apartment Boom

Updated Category News Views 2

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Continue Reading
Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 5

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 7

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
Anecdotes by Artists Brings Raw Scent Stories to Sephora

Updated Category News Views 2

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Continue Reading

Top 5 Most Recently Viewed Articles

RCI Banque Releases Pillar III Report for 2024

Updated Category News Views 211

RCI Banque: Highlights from the Pillar III Report for 2024 RCI Banque has released its Pillar III Report, which contains essential financial and risk management data as of June 30, 2024. This report plays a vital role in ensuring transparency about the bank's risk exposures and capital requirements. What is the Pillar III Report? The Pillar III Report is a crucial element...

Continue Reading
Popsmith Popper Recognized in Oprah’s 2024 Gift List

Updated Category News Views 401

Popsmith Celebrated in Oprah’s Favorite Things List for 2024 In an exciting announcement from Seattle, Popsmith is thrilled to reveal that its signature product, the Popsmith Popper, has been selected for the esteemed Oprah’s Favorite Things holiday gifts list for 2024. This recognition not only highlights the fantastic functionality of their popcorn maker, but also...

Continue Reading
Lyell Immunopharma Secures Major Funding for Innovative Therapies

Updated Category News Views 283

Lyell Immunopharma's Strategic Funding Announcement Lyell Immunopharma, Inc. (NASDAQ: LYEL), a pioneering clinical-stage company, recently declared an exciting advancement in their funding strategy with a private placement of equity aimed at generating up to $100 million. This initiative signifies a robust step forward in their mission to develop next-generation CAR...

Continue Reading
Caterpillar Transitions Leadership with New CEO and Executive Chairman

Updated Category News Views 313

Caterpillar's Leadership Transition: A New Era Begins Caterpillar Inc. recently announced a significant shift in its leadership, marking the end of an era for one of its most prominent figures. After nearing half a century with the company, D. James Umpleby III, the Chairman and CEO, will transition to the role of Executive Chairman of the Board. Meanwhile, Joseph E....

Continue Reading
Levi & Korsinsky Files Class Action for Red Cat Holdings (RCAT)

Updated Category News Views 152

Levi & Korsinsky Takes Action for Red Cat Holdings Investors Levi & Korsinsky, LLP, a prominent securities law firm, has stepped forward to notify investors of Red Cat Holdings, Inc. regarding a class action lawsuit. This action specifically targets individuals who invested in Red Cat Holdings, Inc. (RCAT) and may have suffered losses due to alleged fraudulent activities....

Continue Reading